Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

To participate in this activity, please:

Cutaneous melanoma, historically a rare disease, has continued to see increased incidence over the past several decades. Fortunately, this has been accompanied by increased understanding of the pathobiology, leading to the development of immunotherapy and targeted therapies. In this activity, melanoma specialist Jason J. Luke, MD, FACP, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability by patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.

Course Credit:

0.5 AMA PRA Category 1 CreditsTM


Opens: 2023-10-25
Closes: 2024-10-25

Target Audience:

This activity is intended for medical oncologists, dermatologists, surgeons, and other clinicians who care for people with or at risk for cutaneous melanoma.

This activity is supported by an educational grant from Bristol Myers Squibb.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Chris Elder, PharmD, BCOP (Medical Writer)

Advisory Board: Eisai, Genentech, Mirati, Novartis, Pfizer, Pharmacosmos, Sanofi

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jason J. Luke, MD, FACP

    Associate Professor of Medicine
    Director of Cancer Immunotherapeutics Center
    University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania

Learning Objectives

  • Identify molecular treatment targets for melanoma
  • Compare various treatment considerations for adjuvant/neoadjuvant therapy in early-stage melanoma
  • Create individualized, guideline-recommended treatment strategies, including sequencing considerations, for frontline and later lines of therapy in patients with metastatic melanoma

Faculty Disclosures

Jason J. Luke, MD, FACP

Advisory Board: (no stock) 7 Hills, Affivant, BioCytics, Bright Peak, Exo, F-star, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTX, OncAI, OncoNano, physIQ, Pyxis, Saros, STipe, Tempest

Consultant: AbbVie, Agenus, Alnylam, AstraZeneca, Atomwise, Bayer, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, Ikena, Immatics, Immunocore, IO Biotech, Incyte, Instil, Inzen, Janssen, Kadmon, KoBioLabs, Krystal, KSQ, LegoChem, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimmune, Ribon, Roivant, Servier, Stingthera, Sumoitomo, Synlogic, Synthekine, Teva

Data and Safety Monitoring Board (DSMB): AbbVie, Agenus, Evaxion, Immutep

Research Support: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Novartis, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor